Jordan Cunningham
Family · Lake City, FLNPI 1457899577
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 152 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 31 manufacturers reported payments, led by Novo Nordisk at 26.6% of the total. Reporting peaked in 2021 at $1,209 and has fallen 64.2% since, to $433 in 2025.
Across 152 payments — averaging $17.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$691
- Johnson & Johnson$260
- Novartis$239
- SK Life Science, Inc.$232
- Lilly USA, LLC$112
- Amgen$102
- plus $963 from 25 others
What the payments were for
- Food & beverage$2,599100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 40 | $691 |
| Johnson & Johnson | 22 | $260 |
| Novartis | 17 | $239 |
| SK Life Science, Inc. | 2 | $232 |
| Lilly USA, LLC | 6 | $112 |
| Amgen | 7 | $102 |
| AbbVie | 6 | $100 |
| Merck | 6 | $86 |
| Pfizer | 5 | $75 |
| Teva Pharmaceuticals USA, Inc. | 5 | $72 |
| Sanofi-aventis U.S. LLC | 4 | $70 |
| Mylan Specialty L.p. | 2 | $53 |
| Biogen | 3 | $51 |
| Jazz Pharmaceuticals Inc. | 3 | $50 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $41 |
| Exact Sciences | 2 | $40 |
| Bayer | 2 | $33 |
| AstraZeneca | 2 | $29 |
| Boehringer Ingelheim | 2 | $28 |
| Esperion Therapeutics, Inc. | 2 | $27 |
| Dexcom, Inc. | 1 | $24 |
| Insulet Corporation | 1 | $22 |
| Biohaven Pharmaceuticals, Inc. | 1 | $21 |
| GSK | 1 | $21 |
| Boston Scientific | 1 | $20 |
| Supernus Pharmaceuticals, Inc. | 1 | $19 |
| AMAG Pharmaceuticals, Inc. | 1 | $18 |
| Currax Pharmaceuticals LLC | 1 | $16 |
| Lundbeck LLC | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,599 in reported general payments places this provider in the 85th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 67 | $91,425 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 36 | $29,513 |
| EliquisApixaban | 28 | $26,751 |
| JardianceEmpagliflozin | 26 | $24,004 |
| FarxigaDapagliflozin Propanediol | 12 | $16,813 |
| JanuviaSitagliptin Phosphate | 20 | $14,151 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $9,107 |
| Incruse ElliptaUmeclidinium Bromide | 13 | $4,636 |
| Atorvastatin Calcium | 217 | $1,843 |
| Omeprazole | 91 | $1,704 |
| Rosuvastatin Calcium | 133 | $1,479 |
| Duloxetine Hcl | 31 | $1,371 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 49 | $1,086 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 37 | $1,012 |
| Levothyroxine Sodium | 111 | $990 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $691 | $91,42567 claims |
| GSKTrelegy Ellipta, Incruse Ellipta | $21 | $34,14949 claims |
| PfizerEliquis | $75 | $26,75128 claims |
| Boehringer IngelheimJardiance | $28 | $24,00426 claims |
| AstraZenecaFarxiga | $29 | $16,81312 claims |
| MerckJanuvia | $86 | $14,15120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 14,618 family providers in Florida.
Other family in Lake City
- Lewis HarringtonTampa$954K
- Danielle PharesFt Lauderdale$713K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
- Deena RodneyMaitland$323K
- Yamila MelendezMiami$212K
- Holly BoydLand O Lakes$200K
- Rachael BuschLoxahatchee$189K
- Victor Tatis de la NuezMiramar$161K
- Ronda CrewsJax Bch$155K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.